Cargando…
Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease
INTRODUCTION: We evaluated the selective M1 muscarinic positive allosteric modulator, MK-7622, as adjunctive cognitive enhancing therapy in individuals with Alzheimer's disease. METHODS: A randomized, double-blind, proof-of-concept trial was performed. Participants with mild-to-moderate Alzheim...
Autores principales: | Voss, Tiffini, Li, Jerry, Cummings, Jeffrey, Farlow, Martin, Assaid, Christopher, Froman, Samar, Leibensperger, Heather, Snow-Adami, Linda, McMahon, Kerry Budd, Egan, Michael, Michelson, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021552/ https://www.ncbi.nlm.nih.gov/pubmed/29955661 http://dx.doi.org/10.1016/j.trci.2018.03.004 |
Ejemplares similares
-
Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial
por: Herring, W. Joseph, et al.
Publicado: (2020) -
Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder
por: Connor, Kathryn M, et al.
Publicado: (2017) -
Proof of concept demonstration of optimal composite MRI endpoints for clinical trials
por: Edland, Steven D., et al.
Publicado: (2016) -
Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease
por: Egan, Michael F., et al.
Publicado: (2019) -
Future-proofing extensive livestock production in subtropical grasslands and savannas
por: Kirkman, Kevin P, et al.
Publicado: (2023)